[Risk of atherosclerosis development in patients with systemic lupus erythematosus].
Kotyla
Przemysław J
PJ
Katedra i Klinika Chorób Wewnetrznych i Reumatologii Sl. AM w Katowicach. pkotyla@slam.katowice.pl
Sliwińska-Kotyla
Bogna
B
Lewicki
Maciej
M
Kucharz
Eugeniusz J
EJ
D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000139:chemically induced / Q000453:epidemiology*; D001323:Autoantibodies / Q000009:adverse effects / Q000097:blood; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015984:Causality; D015897:Comorbidity; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D009203:Myocardial Infarction / Q000453:epidemiology; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D016572:Cyclosporine; D001379:Azathioprine